← Eichor
Study identifier: NCT05780684 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer

Condition: Colorectal Cancer · Esophagus Cancer · Appendix Cancer  ·  Sponsor: Dartmouth-Hitchcock Medical Center

PhaseNA
Planned participants36
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose. Study participants will also receive oxaliplatin chemotherapy together with 5-FU, at standard doses. The goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses.

This description comes directly from the study's public registry record.

Talk to the study team

Research Nurse  ·  603-653-3637  ·  cancer.research.nurse@hitchcock.org

Always discuss trial participation with your own doctor first.

Locations (1)

Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05780684